The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BPTH | N/A | N/A | N/A | -100% |
| S&P | +11% | +85.61% | +13.15% | +389% |
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | -28.1% |
| Market Cap | $1.41M | 0.0% |
| Market Cap / Employee | $0.14M | 0.0% |
| Employees | 10 | 0.0% |
| Net Income | -$4.60M | -146.0% |
| EBITDA | -$4.52M | -50.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.48M | 770.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -420.09% | -220.9% |
| Return On Invested Capital | -2039.71% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.28M | 91.2% |
| Operating Free Cash Flow | -$0.28M | 91.2% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Book | 6.36 | -0.55 | - | ||
| Price to Tangible Book Value | 6.36 | -0.55 | - | ||
| Enterprise Value to EBITDA | -0.85 | -2.17 | -0.43 | -0.42 | -272.98% |
| Return on Equity | -430.8% | -366.2% | -1159.7% | -3325.7% | 1411.55% |
| Total Debt | $0.03M | $0.08M | $0.32M | $0.48M | 770.91% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
